The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2022 | The safety and efficacy of belantamab mafodotin in R/R multiple myeloma in the real world
Iuliana Vaxman, MD, Mayo Clinic, Rochester, MN, shares the results of a study investigating the outcomes of 36 patients with relapsed/refractory (R/R) multiple myeloma treated with belantamab mafodotin in Mayo Clinic. The study found that whilst the efficacy of this drug was similar to that observed in the DREAMM-2 trial (NCT03525678), patients treated in Mayo Clinic experienced less treatment-related adverse events. In addition, Dr Vaxman explains that it is important to determine the best dosing schedule for this drug as well as to better manage toxicities. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
